UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~June~~October 627, 2005

SEROLOGICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	0-26126	58-2142225
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employee Identification No.)

5655 Spalding Drive, Norcross, GA		30092
(Address of Principal Executive Offices)		(Zip Code)

(678) 728-2000
(Registrant’s telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Section 1~~Item –2.02. ~~Registrant’s Business~~Results ~~and~~of Operations and Financial Condition.

~~Item~~On October 27, ~~1.01~~2005, ~~Entry~~we ~~into~~issued a ~~Material~~press ~~Definitive~~release ~~Agreement~~regarding our financial results for the quarter ended October 2, 2005. The full text of the press release is attached hereto as Exhibit 99.1.

~~On May 11, 2005, the~~Certain ~~stockholders~~ of ~~Serologicals Corporation (~~the ~~“Registrant”)~~information ~~approved~~set ~~the Serologicals~~forth ~~Corporation~~in ~~2005 Incentive Plan (~~the ~~“Plan”),~~press asrelease ~~reported~~may onbe aconsidered ~~Form 8~~non-KGAAP ~~filed~~financial ~~on May 17, 2005~~measures. ~~Effective~~ ~~on June 6,~~We ~~2005,~~are ~~the~~reporting ~~Registrant~~pro ~~amended~~forma ~~and~~results ~~restated~~for ~~the~~net ~~Plan~~income ~~to clarify certain of the terms~~ and ~~conditions of the awards that may be granted under the~~ ~~Plan~~earnings ~~and~~per ~~limitations~~share onin ~~the~~addition ~~acceleration~~to, and ~~vesting~~not ofas ~~awards~~a ~~granted~~substitute ~~under the Plan. A copy of the Plan~~for, asfinancial ~~amended~~measures ~~and~~calculated ~~restated,~~in isaccordance ~~attached~~with ~~hereto as Exhibit 99~~GAAP.1.

The financial ~~amendments~~results tothat ~~the~~we ~~Plan include~~report ~~the~~on ~~following: (i)~~ the ~~number~~basis of ~~shares~~GAAP ~~subject~~include tosubstantial ~~awards granted~~cash ~~pursuant~~and tonon-cash ~~the~~charges ~~Plan~~and intax ~~any~~benefits ~~fiscal~~related ~~year~~to ~~will~~our ~~not~~numerous ~~exceed~~acquisitions over the ~~sum~~past ofthree ~~(x) 2~~years.5% ~~of the~~We ~~number~~are ofpresenting ~~shares~~pro offorma ~~the~~financial ~~Registrant’s~~information ~~common stock outstanding~~ in ~~such~~the ~~fiscal~~press ~~year~~release ~~and~~because ~~(y)~~we ~~the~~believe ~~number of shares represented by awards~~ that ~~expire or are terminated or forfeited during such fiscal year; (ii)~~ the ~~term~~information ofis ~~all~~a beneficial ~~options,~~supplemental ~~performance~~disclosure ~~share~~to ~~units,~~investors ~~stock~~in ~~appreciation~~analyzing ~~rights~~ and ~~other stock-based~~assessing ~~awards~~our ~~granted~~past ~~under the Plan will not exceed seven years; (iii) the~~and ~~performance~~future ~~cycle for any award that vests upon the achievement of~~ performance ~~goals~~. ~~will~~We ~~not~~believe ~~be less than one year; (iv)~~ the ~~vesting~~pro ~~period~~forma ~~for~~financial ~~any award~~information ofis ~~restricted~~useful ~~stock~~because, among ~~restricted stock units or~~ other ~~stock-based~~things, ~~awards that~~by ~~vests~~eliminating ~~upon~~ the ~~passage~~effect of one-time ~~(other~~acquisition ~~than~~and integration ~~awards~~costs ~~issued~~and to the ~~Registrant’s non-employee~~related ~~directors)~~tax ~~will~~benefits, ~~not~~it beprovides ~~less~~an ~~than~~indication ~~three years; and (v) certain~~of ~~limits apply to~~ the ~~Registrant’s~~profitability ~~ability~~and tocash ~~accelerate~~flows ~~the vesting~~ of ~~awards issued pursuant to~~ the ~~Plan~~acquired businesses.

~~Section 8~~Our pro –forma ~~Other~~financial ~~Events~~information, excluding acquisition related amortization and other similar costs, is limited because it does not reflect the entirety of our business costs. Therefore, we encourage investors to consider carefully our results under GAAP, as well as our pro forma disclosures and the reconciliation between these presentations to more fully understand our business. Reconciliations between our GAAP results and the pro forma information are presented in the tables attached to our press release and also on our web site (www.serologicals.com) under the Investor Relations tab.

Item 8.01 Other Events

On June 10, 2005, the Registrant’s Board of Directors authorized a stock repurchase program to repurchase up to 2.0 million shares of the Registrant’s common stock over the next three years ending in June 2008. The program is intended to be implemented through purchases made from time to time in the open market or through private transactions in accordance with applicable securities laws. The timing, pricing and size of purchases will depend on market conditions, prevailing stock prices and other considerations. The Registrant issued a press release on June 10, 2005 announcing the stock repurchase program, a copy of which is attached hereto as Exhibit 99.2.

Section 9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(a) Not applicable.

(b) Not applicable.

Exhibit		Description
99.1		Serologicals Corporation ~~Amended~~press ~~and~~release ~~Restated~~dated ~~2005~~October ~~Incentive~~27, ~~Plan~~2005
99.2		Press Release issued on June 10, 2005 with respect to stock repurchase program

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SEROLOGICALS CORPORATION By: /s/ ~~HAROLD~~PHILIP WA. ~~INGALLS~~THEODORE Name: ~~Harold~~Philip WA. ~~Ingalls~~Theodore Title: Vice President, ofGeneral ~~Finance and Chief Financial Officer~~Counsel

Date: ~~June~~October 1028, 2005

EXHIBIT INDEX

Number		Description
99.1		Serologicals Corporation ~~Amended~~press ~~and~~release ~~Restated~~dated ~~2005~~October ~~Incentive~~27, ~~Plan~~2005
99.2		Press Release issued on June 10, 2005 with respect to stock repurchase program

Filing Compare · SEROLOGICALS CORP